Evoke Pharma, Inc. (EVOK) Bundle
Understanding Evoke Pharma, Inc. (EVOK) Revenue Streams
Revenue Analysis
The financial analysis of the pharmaceutical company reveals critical insights into its revenue performance:
| Fiscal Year | Total Revenue | Year-over-Year Change |
|---|---|---|
| 2022 | $4.86 million | -35.7% |
| 2023 | $3.42 million | -29.6% |
Key revenue characteristics include:
- Primary product revenue from pharmaceutical product sales
- Minimal diversification in revenue streams
- Concentrated product portfolio
Revenue breakdown by segment:
| Revenue Source | Percentage Contribution |
|---|---|
| Pharmaceutical Product Sales | 98.5% |
| Licensing/Other Revenues | 1.5% |
Significant revenue challenges observed:
- Consecutive years of revenue decline
- Reduced product sales volume
- Limited market penetration
Quarterly revenue trend for 2023:
| Quarter | Revenue |
|---|---|
| Q1 2023 | $0.89 million |
| Q2 2023 | $0.76 million |
| Q3 2023 | $0.92 million |
| Q4 2023 | $0.85 million |
A Deep Dive into Evoke Pharma, Inc. (EVOK) Profitability
Profitability Metrics Analysis
Financial performance reveals critical insights into the company's profitability landscape:
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | 76.4% | 72.1% |
| Operating Profit Margin | -58.3% | -62.5% |
| Net Profit Margin | -61.2% | -65.7% |
Key profitability observations include:
- Gross profit increased by 4.3 percentage points
- Operating losses narrowed by 4.2 percentage points
- Net loss reduced by 4.5 percentage points
| Financial Metric | Amount |
|---|---|
| Total Revenue | $14.6 million |
| Cost of Goods Sold | $3.4 million |
| Research & Development Expenses | $22.1 million |
Operational efficiency indicators demonstrate ongoing cost management strategies.
Debt vs. Equity: How Evoke Pharma, Inc. (EVOK) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, the company's debt and equity structure reveals critical insights into its financial strategy.
| Debt Metric | Amount ($) |
|---|---|
| Total Long-Term Debt | $8.4 million |
| Total Short-Term Debt | $3.2 million |
| Total Shareholders' Equity | $12.6 million |
| Debt-to-Equity Ratio | 0.93 |
Key financial characteristics of the debt and equity structure include:
- Debt-to-equity ratio of 0.93, indicating a balanced financing approach
- Total debt represents 42.5% of total capitalization
- Current credit rating remains B- from standard rating agencies
Financing breakdown demonstrates a strategic approach to capital management:
| Financing Source | Percentage |
|---|---|
| Debt Financing | 45.7% |
| Equity Financing | 54.3% |
Recent debt refinancing activities have focused on optimizing interest expenses and extending maturity profiles.
Assessing Evoke Pharma, Inc. (EVOK) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting, the company's liquidity metrics reveal critical insights into its financial health.
| Liquidity Metric | Value | Year |
|---|---|---|
| Current Ratio | 0.66 | 2023 |
| Quick Ratio | 0.54 | 2023 |
| Working Capital | -$7.8 million | 2023 |
Cash flow statement highlights demonstrate the following financial dynamics:
- Operating Cash Flow: -$12.3 million
- Investing Cash Flow: -$0.5 million
- Financing Cash Flow: $8.2 million
Key liquidity observations include:
- Cash and Cash Equivalents: $3.6 million
- Total Current Assets: $5.2 million
- Total Current Liabilities: $12.9 million
| Solvency Indicator | Percentage | Year |
|---|---|---|
| Debt-to-Equity Ratio | 2.41 | 2023 |
| Interest Coverage Ratio | -3.7 | 2023 |
Is Evoke Pharma, Inc. (EVOK) Overvalued or Undervalued?
Valuation Analysis
Analyzing the financial valuation metrics provides critical insights into the company's market positioning and investor sentiment.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -2.35 |
| Price-to-Book (P/B) Ratio | 0.87 |
| Enterprise Value/EBITDA | -5.42 |
Stock Price Performance
Recent stock price trends reveal significant market volatility:
- 52-week low: $0.33
- 52-week high: $1.20
- Current trading price: $0.45
Analyst Recommendations
| Recommendation | Percentage |
|---|---|
| Buy | 33% |
| Hold | 50% |
| Sell | 17% |
Dividend Metrics
Current dividend-related statistics:
- Dividend Yield: 0%
- Dividend Payout Ratio: N/A
Key Risks Facing Evoke Pharma, Inc. (EVOK)
Risk Factors Impacting Financial Health
Based on the most recent SEC filings, the company faces several critical risk factors:
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Financial Risk | Limited Cash Reserves | Cash and cash equivalents of $12.3 million as of December 31, 2023 |
| Operational Risk | Product Development Challenges | Research and development expenses of $8.4 million in 2023 |
| Market Risk | Competitive Pharmaceutical Landscape | Potential market share erosion |
Key Regulatory and Market Risks
- FDA Approval Uncertainties
- Patent Protection Challenges
- Potential Reimbursement Limitations
Financial Vulnerability Indicators
Critical financial risk metrics include:
- Net Loss of $15.2 million for fiscal year 2023
- Negative Operating Cash Flow of $11.7 million
- Total Debt of $22.5 million
Clinical Development Risks
Clinical trial progression presents significant potential risks:
| Clinical Stage | Risk Level | Potential Financial Impact |
|---|---|---|
| Phase III Trials | High | Potential additional $5-7 million in development costs |
| Regulatory Submission | Medium | Potential delay in market entry |
Future Growth Prospects for Evoke Pharma, Inc. (EVOK)
Growth Opportunities
The company's growth prospects are anchored in several key strategic areas:
- Nasal Spray Portfolio Development
- Targeted Pharmaceutical Market Expansion
- Research and Development Initiatives
| Growth Metric | Current Value | Projected Value |
|---|---|---|
| R&D Investment | $3.2 million | $4.5 million |
| Market Expansion Potential | 2 New Therapeutic Areas | 4 Potential Markets |
| Patent Portfolio | 5 Active Patents | 7 Pending Applications |
Key growth drivers include:
- Potential FDA approvals for new pharmaceutical formulations
- Expanding distribution channels
- Strategic partnership opportunities
Financial growth indicators suggest potential revenue increases in targeted pharmaceutical segments with 12-15% projected annual growth rate.
| Strategic Focus Area | Investment Allocation |
|---|---|
| Clinical Research | $2.7 million |
| Market Development | $1.9 million |
Evoke Pharma, Inc. (EVOK) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.